AMR is a growing problem that threatens our ability to effectively prevent and treat an ever-increasing range of infections caused by bacteria, parasites, viruses, and fungi.1,2
According to the Centers for Disease Control and Prevention (CDC), antibiotic resistance contributes to at least 2.8 million antibiotic-resistant infections and 35,000 deaths each year in the United States.1
AMR develops when microorganisms and parasites evolve to withstand the effects of antimicrobial therapies that would have previously killed them or prevented their growth.1,3,4
An example of this is antibiotic resistance, which emerges when bacteria develop characteristics that allow them to survive exposure to the antibiotics used to treat bacterial infections, eventually making them ineffective.5
Action to halt the evolution and spread of antimicrobial-resistant organisms, coupled with the innovative research and development of novel agents, is vital if we are to maintain an effective repertoire of antimicrobials to treat infection.6
Pneumonia is an acute infection of the pulmonary parenchyma caused by viral, bacterial, and fungal pathogens, causing mild to severe illness, affecting people at any age.7-9
CAP refers to cases of pneumonia that develop in patients outside of the healthcare setting and is a substantial cause of morbidity and mortality in the U.S.10 Together with influenza, pneumonia was the eighth leading cause of death in the U.S. in 2018.11
Streptococcus pneumoniae is the most common bacterial pathogen in patients with CAP and has been classified by the CDC as a serious threat based on the current rates of resistance to commonly used antibiotics, including azithromycin, doxycycline, and penicillin.1,12
SSTIs refer to a diverse collection of clinical infections involving the layers of the skin and its associated underlying soft tissues.13,14
SSTIs are estimated to cause up to 6.3 million office visits, 3.4 million emergency department visits, and 870,000 hospital admissions annually in the United States.15-17
Methicillin-resistant Staphylococcus aureus accounts for nearly half of all S. aureus-related SSTIs and has been identified by the CDC as a serious threat based on resistance to many first-line antibiotics.1,18
The rise of antibiotic resistance underlines the need for the development of new and effective antibiotics to treat infections that have become resistant to existing medications.3
Paratek Pharmaceuticals, Inc. has developed an educational website to provide physicians and healthcare professionals resources to help understand AMR and manage CAP and SSTIs.
The website provides relevant information on CAP and SSTI disease states, symptoms, diagnosis, microbiology, pathogenesis, treatment, epidemiology, disease burden, and the unmet needs, as well as additional resources including current treatment guidelines and recent antimicrobial surveillance data.
To access the website and resources available, please enter through the following link: https://www.infectionsandamr.com/understanding-microbial-infections-and-antimicrobial-resistance-amr
The posting of sponsored information and content on this page should not be considered an AAFP endorsement or recommendation of the sponsor's products, services, policies, or procedures. The information and opinions expressed on this page are those of the paid sponsors and do not necessarily reflect the view of the AAFP. The AAFP is not responsible for the content of third-party websites linked from this page; moreover, any links on this page to third-party websites where goods or services are advertised are not endorsements or recommendations by the AAFP of the third-party sites, goods, or services.